Myocardial infarction model developed using cardiomyocytes

Researchers at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences developed a model of myocardial infarction using cardiomyocytes differentiated from human induced pluripotent stem cells.

The journal Biochemical and Biophysical Research Communications published the study, with Ken Takahashi, Ph.D., as corresponding author, and Wei Heng, MSc., a graduate student in the Naruse Lab, as first author.

To date, laboratory animals such as mouse have been used to model diseases including myocardial infarction. However, there have been concerns about difference in characteristics of cardiomyocytes e.g. heart rate and action of drugs, based on the difference of gene expression between laboratory animals and human.

Using this model, researchers can evaluate the extent of myocardial tissue damage by microscope morphologically, and by measuring injury-marker proteins and analyzing contractility and its synchroneity from recorded movie quantitatively. Further analysis revealed that gene expression of interleukin-8, an inflammation marker known to increase in acute myocardial infarction, increased in this model.

This myocardial infarction model will contribute to the development of preventive/therapeutic medicine more effective to human even without sacrificing animals.

Ken Takahashi, Ph.D., assistant professor in the university and lead author of the study

Source:
Journal reference:

Wei, H. et al. (2019) Development of a model of ischemic heart disease using cardiomyocytes differentiated from human induced pluripotent stem cells. Biochemical and Biophysical Research Communications. doi.org/10.1016/j.bbrc.2019.09.119

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Heart failure mortality declines in Sweden over two decades